Results 121 to 130 of about 580 (130)

Complex DDI by Fenebrutinib and the Use of Transporter Endogenous Biomarkers to Elucidate the Mechanism of DDI

Clinical Pharmacology and Therapeutics, 2020
Leslie W Chinn, Kenta Yoshida, Jane R Kenny   +2 more
exaly  

Fenebrutinib unterdrückt MS-Aktivität

InFo Neurologie + Psychiatrie
openaire   +1 more source

Wirksamkeit von Fenebrutinib für Multiple Sklerose bestätigt

DNP – Die Neurologie & Psychiatrie
openaire   +1 more source

MS: Fenebrutinib punktet in weiterer Phase-III-Studie

NeuroTransmitter
openaire   +1 more source

Duftstoff Mix I und falsch-positive Reaktionen – Fenebrutinib bei H1-Antihistaminika- refraktärer chronisch spontaner Urtikaria (CSU) – H1-Antihistaminika verbessern Ansprechen auf die Immuntherapie bei Krebs

Allergologie, 2022
openaire   +1 more source

Efficacy and Safety of Fenebrutinib vs Teriflunomide in Relapsing Multiple Sclerosis: Results of the FENhance 1 and 2 Studies (LS2.005)

Neurology
Jiwon Oh, Amit Bar-Or, Gavin Giovannoni, Maria Pia Sormani, Martin S. Weber, Sharon Stoll, Jacqueline A. Nicholas, H.-Christian von Büdingen, Marquita Decker-Palmer, Anastasia Loukitcheva, Miriam Triyatni, Nan Hu, John N. Ratchford, Julie Napieralski, Alexandra Goodyear, Ludwig Kappos, Stephen Hauser   +16 more
openaire   +1 more source

177. Fenebrutinib Maintains Low Disease Activity in Relapsing Multiple Sclerosis: Results from the FENopta Trial Open-label Extension

Multiple Sclerosis and Related Disorders
Amit Bar-Or, Jiwon Oh, Michal Dufek, Hrvoje Budincevic, Mario Habek, Maresa Caunt, Piia Thomas, Malgorzata Sierzega, David Clayton, Ying-Fang Chen, John N. Ratchford, Alexandra Goodyear, Jelena Drulovic   +12 more
openaire   +1 more source

Efficacy and Safety of Fenebrutinib vs Ocrelizumab in Primary Progressive Multiple Sclerosis: Primary Results of the Phase III FENtrepid Study (S40.004)

Neurology
Amit Bar-Or, Jiwon Oh, Gavin Giovannoni, Maria Pia Sormani, Martin S. Weber, Sharon Stoll, Jacqueline A. Nicholas, H.-Christian von Büdingen, Jon Lopez, Louise Roberts, Miriam Triyatni, Qi Qi, John N. Ratchford, Julie Napieralski, Alexandra Goodyear, Stephen L. Hauser, Ludwig Kappos   +16 more
openaire   +1 more source

Fenebrutinib Maintains Low Disease Activity in Relapsing Multiple Sclerosis: Results from the FENopta Trial Open-label Extension (P8-1.005)

Neurology
Jiwon Oh, Jelena Drulovic, Michal Dufek, Hrvoje Budincevic, Mario Habek, Maresa Caunt, Malgorzata Sierzega, David Clayton, Ying-Fang Chen, Jack Ratchford, Alexandra Goodyear, Amit Bar-Or   +11 more
openaire   +1 more source

Maintien d’une faible activité de la maladie dans la sclérose en plaques récurrente (SEP-R) avec Fenebrutinib : résultats de l’étude d’extension FENopta (NCT05119569)

Revue Neurologique
Christine Lebrun-Frenay, Amit Bar-Or, Jiwon Oh, Dufek Michal, Budincevic Hrvoje, Habek Mario, Drulovic Jelena   +6 more
openaire   +1 more source